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Background: Relapses and, subsequently, readmissions are common in patients with schizophrenia. Psychoeducation
has been shown to reduce the number and duration of readmissions. Yet, only little more than 20% of psychiatric
patients in German speaking countries receive psychoeducation. Among other reasons, costs may be considered
too high by hospitals. The objective of the present study was to test the feasibility of a new cost-efficient approach
in the psychoeducation of patients with schizophrenia. In this study, films were used to impart knowledge about
the illness to inpatients.
Methods: A total of 113 participants were initially included in the study, eleven of which were not included in the
final analyses. Six films about the symptoms, diagnosis, causes, warning signs, treatment of schizophrenia and
about the influence of family members and friends were shown in a group setting in the presence of nursing staff.
All films combined facts, expert opinions, and personal experiences of peers. As the main outcome criterion of this
feasibility pilot study, we measured the effects on knowledge. Secondary outcome measures included compliance,
insight into illness, side effects, and quality of life. Data were collected directly after the intervention and about half
a year afterwards. The number and the duration of readmissions to the hospital were recorded and compared to
the number and duration of prior admissions. Patients were also asked to state their subjective opinion about the
films. Main data analyses were done using paired t-tests and Wilcoxon signed-rank tests. Secondary analyses also
involved ANOVAs and ANCOVAs.
Results: One hundred and two inpatients were included in the data analyses. Showing the films in the tested
setting was shown to be feasible. Knowledge about schizophrenia (p < .001), compliance (ps < .01), insight into
illness (p < .01), and quality of life (p < .001) all increased significantly after patients had watched the films and remained
stable for at least half a year. A vast majority (84.9%) of the patients found the films to be interesting and informative.
Conclusions: Using films to educate inpatients about schizophrenia is a feasible method that is cost- and time-efficient
and well received by the patients.
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Schizophrenia is a disease that often takes a chronic
course. Relapses with and without readmission to the
hospital are common and often associated with medica-
tion non-compliance [1-8]. There are various causes for
non-compliance, including informational deficits, conse-
quences of psychopathological symptoms, such as cogni-
tive impairments or poor insight into illness, subjective
response to medication, and side effects [9-12].
Relapses come at a high price for both the patient and
the health care system. The relationship between non-
compliance and increased costs for treatment has become
apparent in previous research [6,13,14]. Different ap-
proaches have been taken to improve compliance and to
thereby reduce the costs of (partial) non-compliance, sev-
eral of which have been proven to be effective [15]. One
promising approach is psychoecucation [16]. Researchers
found positive effects of psychoeducative programs on
knowledge, compliance, psychopathology, satisfaction with
treatment, and global functioning. They were also related
to a change of illness concept and to fewer relapses as well
as fewer and shorter readmissions to the hospital [17-20].
In a large-scale randomized multicenter study involv-
ing 236 inpatients (Psychosis Information Project Study),
Pitschel-Walz et al. [21] investigated the long-term ef-
fects of a short psychoeducative program on the number
and duration of readmissions, compliance (rated by
treating physician) and global functioning (GAF) 12 and
24 months after index hospitalization. The program
comprised 8 one-hour group sessions, in which patients
received information about symptoms, etiology, treat-
ment, and relapse prevention. Close relatives received a
similar group intervention. For all the outcome variables,
the authors demonstrated positive effects of psychoeduca-
tion on the intervention group compared to a control
group, who received treatment as usual. An increase in
knowledge and an improvement in illness concept were
also observed in a 6-month follow-up questionnaire [22].
Despite the great number of studies demonstrating the
effectiveness of psychoeducative programs and calls for
them to be a part of standard treatment [16], this form of
intervention is still not implemented across the board.
According to a study investigating the implementation
of psychoeducation for schizophrenia, in 2003, programs
were offered by 83% of hospitals in Germany, Austria,
and Switzerland. However, overall, only 21% of the pa-
tients received psychoeducation. Dropout was high with a
rate of 25% [23,24]. Several factors may have contributed
to this situation. Some hospitals may still question the
effectiveness of such programs, but most of the hospitals
simply do not have enough staff to provide a well-
prepared weekly psychoeducation program for their pa-
tients. And even for those who do, reaching their patients
seems to be a difficult task. In some patients, symptomsmay be too severe. Others are discharged (with or against
medical advice) before they complete the program, and
some patients lack the motivation to join or complete the
program. While, from the hospital’s and the patient’s point
of view, many of these reasons for not offering or partici-
pating in psychoeducation are understandable, the costs
are high. Rummel-Kluge et al. estimated that up to 150
million Euros could be saved each year by tripling the
number of patients receiving psychoeducation [23].
The aim of the pilot study reported here was to inves-
tigate the feasibility of a short, time- and cost-efficient
tool for psychoeducation, which would also be well-
received by patients. To tackle the issue of psychoeduca-
tion being too time consuming and expensive, we used a
program consisting of six films, in which the main topics
concerning schizophrenia and its treatment are covered
[17]. The patients’ motivation was addressed by making
the films shorter than the usual one-hour program and by
presenting facts more vividly by backing them up through
expert opinions and by adding stories of other patients’
personal experiences. Previous research showed that peers
as counsellors and educators are very well received by psy-
chiatric patients [25-27]. In a quasi-experimental pre-post
design, several measures were assessed. As the main out-
come variable, we measured the patients’ knowledge about
their illness before and after the intervention. Secondary
outcome variables included the number and duration of
readmissions, compliance, insight into illness, side effects,
and quality of life. Most of these measures were assessed
before, immediately after the intervention, and approxi-
mately half a year after the intervention. Compliance was
measured before and half a year after the intervention. Re-
admission data were taken from the hospital data base. In
addition, patients were asked to state their personal opin-
ion on the content and on the interestingness of the films.
Both objective and subjective measures were used to gain
insight into the feasibility of this new approach.
Methods
Intervention
Six films of about 17 minutes in length each were used
for this psychoeducative program. Originally, the films
were part of a larger psychoeducation program (Alliance
Psychoeducation Program [17]). The script was written
by two of the authors of the present study and the films
were produced by a professional company. The films were
very well received by patients who participated in the
evaluation of the Alliance Psychoeducation Program, lead-
ing up to the idea to use the films standalone. They in-
cluded objective information about schizophrenia given
by a presenter. Objective information was accompanied
by clips in which patients gave statements about their
personal experiences. Information about the treatment of
schizophrenia was given by experts. Films were presented
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nia, 2. diagnosis of schizophrenia and dealing with schizo-
phrenia, 3. causes of schizophrenia, 4. medication effect
and side effects, 5. warning signs before relapse, 6. influ-
ence of family members and friends) with each of the
cycles lasting two weeks. On average, patients watched
three films per week. They could enter the program at
any point, starting with the film that was presented
next. A member of the nursing staff was always present,
but did not actively interfere with the program. How-
ever, the nurse was allowed to respond to questions. At
the end of each session, patients were asked to give a
short, written evaluation of the film. A session lasted for
about 35 minutes, including the evaluation.
Patients received standard psychiatric care with psycho-
pharmacological treatment. Written informed consent from
each patient and institutional review board approval were
obtained (Ethics Committee of the Faculty of Medicine,
Technische Universität München, Germany).
Participants
A total of 113 patients from a psychiatric hospital in
Mainkofen, Germany were initially included in the
study. Patients were included if they met the following
criteria: a) aged 18–65, b) diagnosis of schizophrenia or
schizoaffective disorder according to ICD-10, c) accord-
ing to the clinical decision of the treating physician,
psychotic symptoms had decreased enough to be able to
follow psychoeducative content and to fill out question-
naires, d) no signs of organic brain damage or intellec-
tual disability, e) adequate knowledge of the German
language, f ) adequate eye sight, and g) estimated dur-
ation of stay of at least two weeks. Participants were in-
cluded in the data analyses if they had watched at least
five of the six films. Eleven patients did not meet the
criteria (e.g. due to change in diagnosis) and had to be
excluded from data analyses.
Assessment
There were two main measuring points for data assess-
ment: immediately before the intervention (T0) and im-
mediately after the intervention (T1; on average 15 days
after the first assessment). In addition, it was possible to
obtain data from some patients and their physicians a few
months after the intervention to assess the stability of the
effects (T2; for patients on average 150 days and for doc-
tors on average 163 days after the first assessment).
Self-assessment
The Knowledge of Illness about Schizophrenia Ques-
tionnaire [28] was used to assess a potential increase
in knowledge. It is an instrument for assessing know-
ledge of patients with schizophrenia about symptoms,
causes, treatment, and warning signs. It comprises 21questions with 107 single items. The maximum score
is 70 points. The questionnaire is reliable (reliability coeffi-
cient α = .91) [19,29].
In order to assess the adherence to medication, the
Medication Adherence Rating Scale (MARS) was used.
The MARS comprises ten items. The score ranges from
0 to 10 points with 10 points indicating more compli-
ance. The MARS shows high internal consistency with a
Cronbach’s alpha of .75 [30].
In addition, single items were used to assess how well
the patient felt informed about schizophrenia (4-point
scale: 1 – very good, 2 – good, 3 – moderate, 4 – poor),
perceived quality of life (5-point scale: 1 – very poor, 2 –
poor, 3 – average, 4 – good, 5 – very good), contentment
with health (5-point scale: 1 – very discontent, 2 – dis-
content, 3 – neither content nor discontent, 4 – con-
tent, 5 – very content), and the subjective rating of the
strength of medication side effects (Visual Analogue
Scale with 0 indicating strong side effects and 100 indi-
cating no side effects).
External assessment
All external assessments for T0 and T1 were done by
nurses from the hospital. External assessments for T2
were done by the psychiatrist/neurologist or general prac-
titioner, from whom the patient received outpatient treat-
ment at the time. The physicians evaluating T2 measures
were blind to the nurses’ assessment at T0 and T1. Com-
pliance was only measured at T0 and T2, not at T1.
Compliance was rated on a 4-point scale that was
exactly operationalized (1 – very good, 2 – good, 3 – mod-
erate, 4 – poor; see Pitschel-Walz et al. [21] for exact
operationalization) and insight into the illness was rated on
a 3-point scale (1 - insightful, 2 – somewhat insightful, 3 –
not insightful; fourth alternative: not relevant). This item
was taken from the Scale to Assess Unawareness of Mental
Disorder. Inter-rater ICC for the item was .89 [31].
Frequency and duration of (re-)admissions to the hos-
pital were obtained from the hospital data base for
70 weeks prior to the index admission and for 70 weeks
after index discharge.
Immediately after watching a film, participants were
presented with three statements and asked to check a
box if they agreed with them. The statements were the
following: “It was interesting and informative.”, “I already
knew most of the content.”, “I was too troubled by this”.
In addition, they were asked to write down what they
had liked most and what had helped them most.
Statistical analysis
Descriptive methods were used for statistical analyses of
sociodemographic and feedback data from participants.
For Visual Analogue Scales and summed scores, such as
the Knowledge of Illness score and the MARS score as
Table 1 Sociodemographic data of participants, n = 102
Characteristic M SD
Age (years) 35.1 9.0
Duration of Stay (days) 57.4 26.6
Duration of Illness (years) 11.1 10.6







Schizoaffective Disorder 16 15.7
Pharmacological Treatment
Atypical Antipsychotic 74 72.5
Typical Antipsychotic 15 14.7
Both 13 12.7






In training 6 5.9
Competitive employment 23 22.6





With parents/siblings/relatives 40 39.2
With partner/children 25 24.5
In a rehabilitation facility 7 6.9
*Information was available from 96 patients.
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tance and normality [32] were assumed. These compari-
sons were made using paired t-tests. For our primary
outcome measure, the 95% confidence interval of the
difference was analyzed. Comparisons involving all other
data were made using the Wilcoxon signed-rank test.
Exploratory analyses, which are reported in the discus-
sion, were made using ANOVAs to test for an inter-
action of prior treatment with the increase in knowledge
and ANCOVAs to test for the influence of perceived side
effects on compliance. All calculations were done with
PASW statistics, versions 18.0.0 and 20.0.0.2.
Results
Reception of films
Overall, the films were well received by the patients. On
average, 84.9% of the participants thought them to be in-
teresting and informative. To an average of 82.3%, most
of the content of the films was new. Only 7.5% thought
that the films were too upsetting to watch, while 92.5%
did not think so.
Pre-post comparisons
Sociodemographic data are presented in Table 1. Means,
standard deviations, and sample sizes for each dependent
measure are given in Table 2.
Self-assessment
There was a significant increase of 7.3 points in the know-
ledge of illness score, t(91) = −9.87, p < .001. The 95% CI
[5.8, 8.8] of the difference between the two means did
not include the value “0” and therefore corroborates the
finding of a significant increase in our primary outcome
measure.
Patients also scored higher in the MARS, t(72) = −3.90,
p < .001, after they had participated in the psychoeduca-
tion program. They felt more informed about schizo-
phrenia, Z = −6.52, p < .001, rated quality of life higher,
Z = −4.70, p < .001, and felt more content with their
health, Z = −4.21, p < .001. The subjective rating of the
strength of medication side effects did not decrease t < 1.
External assessment
There was a significant increase in the rating of insight
into illness, Z = −2.90, p < .01. However, neither frequency
nor duration of (re-)admissions to the hospital changed
significantly after the intervention, all ps > .140.
Long-term effects
Data for T2 are available from only about half of the pa-
tients. Thus, they were analyzed separately and should
be interpreted carefully.
Compliance, as rated by nurses and doctors, in-
creased significantly, Z = −2.62, p < .01. The knowledgeof illness score was still elevated at T2 when compared
to T0, t(52) = −4.35, p < .001 and did not differ from
T1, t(52) = 0.88, p = .384 (n = 53). The same pattern was
found for the MARS score, T0-T2: t(42) = −2.14, p = .038
and t(42) = 0.15, p = .883 respectively (n = 43), perceived
quality of life, Z = −2.27, p < .05 and Z = −0.66, p = .509
respectively (n = 51), contentment with health, Z = −1.99,
p < .05 and Z = −0.62, p = .533 respectively (n = 51), and
insight into illness, Z = −2.32, p < .05 and Z = −0.57,
p = .567 respectively (n = 49).
Patients still felt more informed about schizophrenia
at T2 when compared to T0, Z = −4.83, p < .001. There
was, however, a small decrease from T1 to T2, Z = -1.96,
p < .05 (n = 54). Again, there were no effects for the
Table 2 Means and standard deviations (in Parentheses) for T0 and T1, as well as sample sizes for each measure
Measure T0 T1 n*
Knowledge of Illness about schizophrenia questionnaire 41.1 (14.2) 48.4 (14.2) 92
MARS 7.2 (2.0) 7.9 (1.8) 73
Insight into Illness 1.6 (0.7) 1.4 (0.6) 91
Feeling of being informed about schizophrenia 2.7 (0.9) 1.8 (0.7) 94
Subjective strength of side effects 65.2 (28.1) 65.8 (25.8) 90
Perceived quality of life 3.0 (1.0) 3.5 (0.9) 92
Contentment with health 3.0 (1.2) 3.5 (1.0) 91
Pre Post N*
Compliance 2.2 (1.0) 1.7 (1.0) 54
Frequency of (re-)admission 0.5 (1.0) 0.6 (0.9) 101
Duration of (re-)admission 22.8 (49.4) 26.3 (42.2) 101
Significant results are indicated by bold text.
*Data were not available from every patient for each outcome measure. As many data points as possible were included in each analysis, causing the sample size
to differ between outcome measures.
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fects, t < 1 (n = 54).Discussion
The present study aimed at investigating the feasibility
of a new approach for psychoeducation that is more time-
and more cost-efficient compared to a standard psychoe-
ducation program, while integrating vital information
about schizophrenia given by professionals with the per-
sonal experience of peers, who patients can relate to. The
intervention proved to be effective in several measures.Knowledge about schizophrenia increased
Patients were more informed about their illness at the
end of the psychoeducation program and seemed to still
remember this information after a few months had
passed. Subjectively, patients also felt more informed
about schizophrenia immediately after the intervention,
but seemed to feel somewhat less confident after a few
months. This effect might be reduced if patients had the
opportunity to visit booster sessions or if the films were
made available for private use, giving further access to
information and to emotional support after being dis-
charged. The two-month period directly following a
hospitalization is especially important for adherence as
the readmission rate is particularly high here [33]. Being
able to watch the films at home may also aid those
patients, who were not able to complete the program at
the hospital due to early discharge and, as a desirable
side effect, this also raises the likelihood of relatives
watching the films. The importance of educating rela-
tives has been shown in many studies, however, it is still
not being done thoroughly in severe mental illnesses,
where stigma and social avoidance remain a serious
problem [16,34-37].Compliance and insight into illness increased
Compliance was also higher after the intervention as
indicated by the self-assessment (MARS) and external
assessment (rated by nurses and doctors). The increase
in compliance seemed to be long-term. Alongside compli-
ance, insight into illness, which might be a crucial pre-
requisite, also increased. Unfortunately, the number of
(re-)admissions did not decrease in the first 70 weeks after
index discharge. However, schizophrenia often takes a
chronic course making readmissions a necessity to protect
the patients from the consequences of their disease. Thus,
readmissions, especially if they happen voluntarily and
early during a relapse, can be considered a success. This
notion is supported by the increase in the quality of life
ratings. Although the patients spent about as much time
in the hospitals as they had done before the index treat-
ment, they were more content with their health and per-
ceived a higher quality of life.
However, compliance may have increased because the
medication started to work, thereby also reducing the
consequences of psychopathological symptoms, such as
impaired cognitive functions and impaired insight into
illness. However, patients were only included in the study
if they were able to follow the content of the films and to
fill out questionnaires, implying the ability to be compli-
ant. In addition, the Clinical Global Impression Severity
score did not change significantly between T0 (M = 5.9,
SD = 0.7) and T1 (M = 5.8, SD = 0.8), p = .354. The pa-
tients’ attitude towards their medication may have been
better due to a better adjustment of that medication at the
end of treatment, causing fewer side effects. However, the
perceived strength of side effects did not differ between
any of the times of measurement. In an ANCOVA with
the perceived strength of side effects at T1 as covariate,
the covariate only influenced the MARS score at a
trend level, F(1,69) = 3.25, p = .076, MSE = 6.14, and did
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F < 1 and F(1,84) = 1.93, p = .168, MSE = 0.58 respect-
ively. For the MARS score, the difference between T0
and T1 remained significant after controlling for the per-
ceived strength of side effects, F(1,70) = 13.53, p < .001,
MSE = 1.10. Future studies, however, should also evalu-
ate cognition, which can be an important factor in
knowledge acquisition.
Films were well accepted
There is evidence that insight into a severe mental ill-
ness is also associated with negative implications such as
self-stigma, shame or lower quality of life [38-40]. The
films might have had a similar effect on the patients in
the present study. However, our results suggest that any
negative effect, if present at all, could not have lasted
long. We would have expected more patients to find the
films upsetting, which was not the case. Also, perceived
quality of life increased in the present study. Any nega-
tive effect of gaining insight through the films may have
been counteracted by the combination of providing facts
and personal experiences of successfully treated patients
in the films.
First and multiple episode patients benefit from the
intervention
Both, first time patients (n = 63; t(62) = −8.74, p < .001)
and others (n = 29, t(28) = −4.84, p < .001) showed a sig-
nificant increase in knowledge. The interaction of prior
treatment with time of measurement for the knowledge
of illness score did not exceed a trend level, F(1,90) =
3.15, p = .079, MSE = 24.84). Importantly, this result in-
dicates that psychoeducation is an effective tool not
only during a patient’s first episode, but also after one or
more relapses.
Limitations
There are certain limitations to this study, the most ob-
vious one being the use of a quasi-experimental design.
Due to the lack of a control group that did not receive
the same treatment as the intervention group, we cannot
rule out beyond any doubt the possibility that our results
were in fact caused by something other than the inter-
vention. For instance, it seems possible that treatment as
usual alone may have caused the effects reported above.
Patients may have learned about schizophrenia from the
hospital staff or from other patients. While this is prob-
ably true to some extent, knowledge would have been
acquired in a less systematic way, causing variance to be
bigger and effects to be smaller. In a previous study,
Pitschel-Walz et al. [22] compared the increase in know-
ledge between an intervention group that participated in
a psychoeducative group program and a control group
that received treatment as usual. An increased score inthe Knowledge of Illness about Schizophrenia Question-
naire was observed for the intervention group only, not
for the control group. Taking these results into consider-
ation, it seems highly unlikely that treatment as usual was
the cause of the effects observed in the present study. In
addition, we would have expected first time patients to
have a much higher increase in knowledge than patients
who had been treated for schizophrenia in a hospital be-
fore. This was not the case. Furthermore, we cannot rule
out the possibility that choosing a mixed diagnoses sample
may have had an influence on the results. The program
was originally planned for patients with a diagnosis of
schizophrenia. Patients who suffer from schizoaffective
disorder differ in some aspects from patients with schizo-
phrenia and may have responded differently to the content
of the films. Unfortunately, the sample of patients with
schizoaffective disorder was too small to be analyzed sep-
arately. Future research needs to determine the effect of
the films on this group of patients.
Conclusions
Using films to educate patients about schizophrenia and
schizoaffective disorder is a cost-saving and time-efficient
approach, which was well received by the vast majority of
our patients. We were able to show positive effects on
knowledge, compliance, insight into illness, and quality of
life after the intervention. Both the short-term and long-
term effects observed here are promising. However, the
findings need to be confirmed by future research and
tested against a suitable control group. Future research
also needs to determine whether psychoeducation via film
is just as effective as other methods, such as standard
group psychoeducation led by an expert or a peer. Psy-
choeducation via film could be a useful tool in different
situations. For instance, it could be used in hospitals that
are short of staff. Patients could start the program at the
hospital and continue watching the films after discharge,
or watch them again later. Relatives would get the chance
of receiving information about schizophrenia, even when
there are no groups offered for them. In addition, these
films could be used to educate new staff. Thus, films could
be a versatile addition to the standard treatment, especially
in view of scarce resources.
Abbreviations
ANOVA: Analysis of variance; ANCOVA: Analysis of covariance; CI: Confidence
interval; MARS: Medication Adherence Rating Scale.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CvM contributed to the study design, performed the acquisition of data and
the data management. FG and CvM performed the statistical analyses and
wrote the paper. CRK conceptualised and coordinated the study, interpreted
the data and revised the paper. WK and WS contributed to the study design
von Maffei et al. BMC Psychiatry  (2015) 15:93 Page 7 of 7and revised the paper for important intellectual content. All authors read
and approved the final manuscript.
Acknowledgements
We acknowledge support from Leipzig University within the program of
Open Access Publishing and we wish to thank the patients and the nursing
staff who participated in this study.
Author details
1Department of Psychiatry and Psychotherapy, University of Leipzig,
Semmelweisstr. 10, D-04103 Leipzig, Germany. 2Forschungszentrum
Depression der Stiftung Deutsche Depressionshilfe, Semmelweisstr. 10, 04103
Leipzig, Germany. 3Department of Psychiatry and Psychotherapy, Technische
Universität München, Möhlstr. 26, 81675 München, Germany. 4Bezirksklinikum
Mainkofen, 94469 Deggendorf, Germany.
Received: 20 November 2014 Accepted: 23 April 2015
References
1. Schooler NR. Relapse and rehospitalization: comparing oral and depot
antipsychotics. J Clin Psychiatry. 2003;64 Suppl 16:14–7.
2. Kissling W, Leucht S. Results of treatment of schizophrenia: is the glass half
full or half empty? Int Clin Psychopharmacol. 1999;14 Suppl 3:S11–4.
3. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk
factors for medication nonadherence in patients with schizophrenia: a
comprehensive review of recent literature. J Clin Psychiatry. 2002;63:892–909.
4. Jeffreys SE, Harvey CA, McNaught AS, Quayle AS, King MB, Bird AS. The
Hampstead Schizophrenia Survey 1991. I: Prevalence and service use
comparisons in an inner London health authority, 1986–1991. Br J
Psychiatry. 1997;170:301–6.
5. Weiden P, Glazer W. Assessment and treatment selection for "revolving
door" inpatients with schizophrenia. Psychiatr Q. 1997;68:377–92.
6. Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, et al.
Adherence to treatment with antipsychotic medication and health care
costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry.
2004;161:692–9.
7. Rummel-Kluge C, Schuster T, Peters S, Kissling W. Partial compliance with
antipsychotic medication is common in patients with schizophrenia. Aust N
Z J Psychiatry. 2008;42:382–8.
8. Gibson S, Brand SL, Burt S, Boden ZVR, Benson O. Understanding treatment
non-adherence in schizophrenia and bipolar disorder: a survey of what
service users do and why. BMC Psychiatry. 2013;13:153.
9. Rettenbacher MA, Hofer A, Eder U, Hummer M, Kemmler G, Weiss EM, et al.
Compliance in schizophrenia: psychopathology, side effects, and patients'
attitudes toward the illness and medication. J Clin Psychiatry. 2004;65:1211–8.
10. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in
schizophrenia: empirical and clinical findings. Schizophr Bull. 1997;23:637–51.
11. Anselmetti S, Bechi M, Bosia M, Quarticelli C, Ermoli E, Smeraldi E, et al.
‘Theory’of mind impairment in patients affected by schizophrenia and in
their parents. Schizophr Res. 2009;115:278–85.
12. Nuechterlein KH, Ventura J, Subotnik KL, Bartzokis G. The early longitudinal
course of cognitive deficits in schizophrenia. J Clin Psychiatry. 2014;75:25.
13. Thieda P, Beard S, Richter A, Kane J. An economic review of compliance
with medication therapy in the treatment of schizophrenia. Psychiatr Serv.
2003;54:508–16.
14. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull.
1995;21:419–29.
15. Nose M, Barbui C, Gray R, Tansella M. Clinical interventions for treatment
non-adherence in psychosis: meta-analysis. Br J Psychiatry. 2003;183:197–206.
16. Bauml J, Frobose T, Kraemer S, Rentrop M, Pitschel-Walz G. Psychoeducation:
a basic psychotherapeutic intervention for patients with schizophrenia and
their families. Schizophr Bull. 2006;32 Suppl 1:S1–9.
17. Rummel-Kluge C, Pitschel-Walz G, Kissling W. A fast, implementable
psychoeducation program for schizophrenia. Psychiatr Serv. 2007;58:1226.
18. Pekkala E, Merinder L. Psychoeducation for schizophrenia. Cochrane
Database Syst Rev. 2011;15(6):CD002831.
19. Pitschel-Walz G. Die Einbeziehung der Angehörigen in die Behandlung
schizophrener Patienten und ihr Einfluss auf den Krankheitsverlauf. In:
Lang P, editor. [Europäische Hochschulschriften. Reihe VI, Psychologie
Publications universitaires européennes. Série VI, Psychologie Europeanuniversity studies. Series VI, Psychology, vol. 581], vol. 19. Frankfurt am Main,
New York; 1997. p. 99–118.
20. Xia J, Merinder LB, Belgamwar MR. Psychoeducation for schizophrenia.
Cochrane Database Syst Rev. 2011.15;(6):CD002831.
21. Pitschel-Walz G, Bauml J, Bender W, Engel RR, Wagner M, Kissling W.
Psychoeducation and compliance in the treatment of schizophrenia: results of
the Munich psychosis information project study. J Clin Psychiatry. 2006;67:443–52.
22. Pitschel Walz G, Boerner R, Mayer CER, Peuker I, Welschehold M, Bender W,
et al. Informationszentrierte gruppen für schizophrene patienten und deren
angehörige: einfluß von wissen, krankheitskonzept und expressed emotions
(PIP-studie). In: Bender W, Hubmann W, Mohr F, editors. Neuere entwicklungen
in der behandlung schizophrener psychosen. München-Haar: VTS-Verlag; 1995.
23. Rummel-Kluge C, Pitschel-Walz G, Bauml J, Kissling W. Psychoeducation in
schizophrenia–results of a survey of all psychiatric institutions in Germany,
Austria, and Switzerland. Schizophr Bull. 2006;32:765–75.
24. Rummel-Kluge C, Kluge M, Kissling W. Frequency and relevance of
psychoeducation in psychiatric diagnoses: results of two surveys five years
apart in German-speaking European countries. BMC Psychiatry. 2013;13:170.
25. Rummel-Kluge C, Stiegler-Kotzor M, Schwarz C, Hansen W, Kissling W.
Peer-counseling in schizophrenia: patients consult patients. Patient Educ
Couns. 2008;70:357–62.
26. McGill CW, Patterson CJ. Former patients as peer counselors on locked
psychiatric inpatient units. Psychiatr Serv. 1990;41:1017–9.
27. Rummel CB, Hansen W, Helbig A, Pitschel-Walz G, Kissling W. Peer-to-peer
psychoeducation in schizophrenia: a new approach. J Clin Psychiatry.
2005;66:1580–5.
28. Bäuml J, Pitschel-Walz G. Psychoedukation bei schizophrenen Erkrankungen:
Konsensuspapier der Arbeitsgruppe "Psychoedukation bei schizophrenen
Erkrankungen". Stuttgart, New York: Schattauer; 2003.
29. Froböse T, Bäuml J, Jahn T, Pohl C, Pitschel-Walz G. Knowledge gain by
psychoeducation for patients with schizophrenia: associations with
sociodemographic data, psychopathology, insight and global neurocognitive
performance. Int J Clin Psychiatry Mental Health. 2014;2:111–21.
30. Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new
medication adherence rating scale (MARS) for the psychoses. Schizophr Res.
2000;42:241–7.
31. Amador XF, Strauss DH, Yale SA, Flaum MM, Endicott J, Gorman JM.
Assessment of insight in psychosis. Am J Psychiatry. 1993;1:873.
32. Hays WL. Statistics for the social sciences. 2nd ed. New York: Holt, Rinehart
and Winston; 1973.
33. Markowitz M, Karve S, Panish J, Candrilli SD, Alphs L. Antipsychotic adherence
patterns and health care utilization and costs among patients discharged after
a schizophrenia-related hospitalization. BMC Psychiatry. 2013;13:246.
34. McFarlane WR, Dixon L, Lukens E, Lucksted A. Family psychoeducation and
schizophrenia: a review of the literature. J Marital Fam Ther. 2003;29:223–45.
35. Cohen AN, Glynn SM, Murray-Swank AB, Barrio C, Fischer EP, McCutcheon
SJ, et al. The family forum: directions for the implementation of family
psychoeducation for severe mental illness. Psychiatr Serv. 2008;59:40–8.
36. Frank F, Rummel-Kluge C, Berger M, Bitzer EM, Holzel LP. Provision of group
psychoeducation for relatives of persons in inpatient depression treatment–a
cross-sectional survey of acute care hospitals in Germany. BMC Psychiatry.
2014;14:143.
37. Farrelly S, Clement S, Gabbidon J, Jeffery D, Dockery L, Lassman F, et al.
Anticipated and experienced discrimination amongst people with
schizophrenia, bipolar disorder and major depressive disorder: a cross
sectional study. BMC Psychiatry. 2014;14:157.
38. Hasson-Ohayon I, Avidan-Msika M, Mashiach-Eizenberg M, Kravetz S,
Rozencwaig S, Shalev H, et a. Metacognitive and social cognition
approaches to understanding the impact of schizophrenia on social quality
of life. Psychiatry Research 2012;200(2-3):802–806.
39. Hasson-Ohayon I, Ehrlich-Ben Or S, Vahab K, Amiaz R, Weiser M, Roe D.
Insight into mental illness and self-stigma: the mediating role of shame
proneness. Psychiatry Res. 2012;200:802–6.
40. Hasson-Ohayon I, Kravetz S, Roe D, David AS, Weiser M. Insight into
psychosis and quality of life. Compr Psychiatry. 2006;47:265–9.
